Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Find generic entry opportunities
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition|
|Abstract:||The use of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine in the treatment of pain and residual symptoms in depression is provided. ##STR00001##|
|Inventor(s):||Moore; Nicholas (Delmar, NY), Stensbol; Tine Bryan (Vaerlose, DK)|
|Assignee:||H. Lundbeck A/S (Valby-Copenhagen, DK)|
|Filing Date:||Mar 14, 2008|
|Claims:||1. A method for the treatment of pain, the method comprising the administration of a therapeutically effective amount of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine or a pharmaceutically acceptable acid addition salt thereof (compound I) to a patient in need thereof. |
2. The method according to claim 1, wherein compound I is the HBr acid addition salt.
3. The method according to claim 2, wherein said HBr acid addition salt is crystalline with XRPD reflections at 6.89, 9.73, 13.78 and 14.64 (.degree. 2.theta.).
4. The method according to claim 3, wherein said HBr acid addition salts has an XRPD as depicted in FIG. 3.
5. The method according to claim 1, wherein compound I is administered in daily doses of about 1-20 mg.